Ines Deleu
Medical oncologist in Sint-Niklaas, Belgium, who enrolled patients in international breast cancer drug trials, including the BOLERO-2 trial of everolimus
Medical oncologist, oncology department, Vitaz hospital, Sint-Niklaas (named in a 2024 news report) · Oncologic Centre, AZ Nikolaas, Sint-Niklaas (PubMed affiliation 2011–2022)
Portrait: ResearchGate
Ines Deleu is a co-author of the two Atlas reports from BOLERO-2, a large trial in postmenopausal women with advanced breast cancer that is driven by hormones (hormone-receptor-positive) and does not carry extra copies of the HER2 gene. These cancers often learn to grow despite hormone treatment, and switching on the mTOR pathway is one way they do it. BOLERO-2 added everolimus, a rapamycin-like drug that blocks mTORC1, the growth-control complex, to the hormone drug exemestane. The first report (BAS2012) showed that the combination kept the cancer from growing for several months longer than exemestane alone. The final report (PIC2014) found that this gain held up, but that overall survival was not significantly longer (31.0 against 26.6 months).
Large cancer trials like this one run at hundreds of hospitals, and site investigators enrol and treat the patients, collect the data and sign off on the final paper. PubMed lists Deleu at AZ Nikolaas, a general hospital in Sint-Niklaas in Flanders, on about a dozen papers, most of them multicentre breast cancer trials. The most recent, from 2022, is the phase III EMERALD trial of elacestrant, an oral drug that breaks down the estrogen receptor.
A 2024 news report on public tours of the oncology department at Vitaz hospital in Sint-Niklaas names Dr. Ines Deleu as the oncologist who leads them, explaining cancer statistics and treatment options to visitors and pointing out a room set up for adolescents and young adults with cancer. No official hospital profile was found, so training details are not given here.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2012 | H | Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer (BOLERO-2) BAS2012 Site investigator and co-author at AZ Nikolaas on BOLERO-2, the trial that added everolimus to exemestane in advanced hormone-receptor-positive breast cancer. |
| 2014 | H | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2† PIC2014 Co-author of the final BOLERO-2 report, which confirmed the gain in progression-free survival but found no significant gain in overall survival. |
Co-authors in the Atlas 14
People with a profile here who share at least one study with Ines Deleu.
ShowHide
- Alejandra Perez 2 shared studies Breast cancer oncologist in South Florida who enrolled patients in BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Fabienne Lebrun 2 shared studies Medical oncologist at the Institut Jules Bordet in Brussels and a co-author of the BOLERO-2 trial reports that brought the mTOR inhibitor everolimus into breast cancer care
- Gabriel N. Hortobagyi 2 shared studies Breast cancer physician-scientist and senior author of BOLERO-2, the phase 3 trial that showed adding the mTOR inhibitor everolimus improves outcomes in advanced hormone-receptor-positive breast cancer
- Hope Rugo 2 shared studies Breast cancer oncologist and clinical trialist, long at UCSF, who helped run BOLERO-2 and studied how to manage the side effects of mTOR inhibitors such as everolimus
- José Baselga 2 shared studies Breast cancer oncologist who led the BOLERO-2 trial showing that the mTOR inhibitor everolimus added to hormone therapy lengthens progression-free survival
- Kathleen Pritchard 2 shared studies Breast cancer medical oncologist at Sunnybrook in Toronto, professor emerita at the University of Toronto and long-time leader of breast cancer trials, co-author of the BOLERO-2 everolimus trial
- Mario Campone 2 shared studies Breast cancer oncologist and general director of the Institut de Cancérologie de l'Ouest, a co-investigator on the BOLERO-2 trial that brought everolimus into breast cancer care
- Martine J. Piccart 2 shared studies Breast cancer oncologist who co-founded the Breast International Group and has led or co-led major academic trials such as HERA, MINDACT and ALTTO.
- Michael Gnant 2 shared studies Surgical oncologist and breast cancer trialist, Professor of Surgery at the Medical University of Vienna and President of the Austrian Breast and Colorectal Cancer Study Group, and a co-author of BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Shinzaburo Noguchi 2 shared studies Breast cancer surgeon and researcher at Osaka University and a co-investigator of BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Yoshinori Ito 2 shared studies Breast medical oncologist at the Cancer Institute Hospital in Tokyo and a co-investigator of BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- David Lebwohl Medical oncologist and drug developer who led the clinical development of everolimus (Afinitor) at Novartis through approvals in several cancers and tuberous sclerosis, and later served as Chief Medical Officer of the gene-editing company Intellia Therapeutics
- Howard A Burris Medical oncologist who led the Sarah Cannon Research Institute in Nashville as President and Chief Medical Officer, has run hundreds of early-phase cancer drug trials, including the first trial of the mTORC1-selective inhibitor RMC-5552, and was ASCO President in 2019–2020
- Tarek Sahmoud Physician and epidemiologist who worked as a clinical program head in Novartis oncology drug development during the everolimus trials, and later as chief medical officer at several cancer drug companies
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.